ArticleiScience2025
Locus-specific human endogenous retroviruses reveal lymphoma subtypes.
Article in iScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- CDK9 Inhibition with enitociclib reveals influence on HERV and LINE RNA abundances in whole blood, T-, and B-Cell lines.BMC medical genomics · 2026Article
- Human endogenous retrovirus profiling reveals heterogenous expression in cutaneous melanoma.Frontiers in oncology · 2026Article
- EBV-miR-BART5-3p promotes the proliferation of Burkitt lymphoma cells via glycolytic pathway.Annals of hematology · 2025Article
- Transposable elements as genome regulators in normal and malignant haematopoiesis.Blood cancer journal · 2025Review
- An integrated approach for the accurate detection of HERV-K HML-2 transcription and protein synthesis.Nucleic acids research · 2025Article
- Endogenous retroelements in hematological malignancies: From epigenetic dysregulation to therapeutic targeting.American journal of hematology · 2025Review
- The Possible Role of Pathogens and Chronic Immune Stimulation in the Development of Diffuse Large B-Cell Lymphoma.Biomedicines · 2024Review
Corrections and comments
- Update of
Authors and funding
14 authors.
Funding
Abstract
The heterogeneity of cancers is driven by diverse mechanisms underlying oncogenesis such as differential 'cell-of-origin' progenitors, mutagenesis, and viral infections. Classification of B cell lymphomas has been defined by considering these characteristics. However, the expression and contribution of endogenous retroelements (EREs) to B cell lymphoma oncogenesis or classification have been overlooked. We hypothesized that incorporating ERE expression signatures would increase the resolution of B cell identity during healthy and malignant conditions. Here, we present the first comprehensive, locus-specific characterization of ERE expression in benign germinal center B cells, diffuse large B cell lymphoma, Epstein-Barr virus (EBV)-positive and EBV-negative Burkitt lymphoma, and follicular lymphoma. Our findings demonstrate unique human ERE signatures in the GC and lymphoma subtypes whose activity can be used in combination with gene expression to define B cell lineage in lymphoid malignancies, highlighting the potential of ERE analyses as a tool in lymphoma classification, diagnosis, and the identification of treatment groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.